Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - clarithromycin - granules for oral suspension - macrolides; clarithromycin

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 250mg;  ; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg   excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol   hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 25 mg/ml;  ;   - granules for oral suspension - 125 mg/5ml - active: clarithromycin 25 mg/ml     excipient: carbomer castor oil citric acid monohydrate fruit mix flavour wl-18758 204264 hydrated silica hypromellose phthalate maltodextrin potassium sorbate povidone sucrose titanium dioxide xanthan gum - klacid suspension is indicated for treatment of infections caused by susceptible organisms. such infections include: ? upper respiratory infections (e.g. streptococcal pharyngitis). ? lower respiratory infections (e.g. bronchitis, pneumonia). ? acute otitis media. ? skin and skin structure infections (e.g. impetigo, folliculitis, cellulitis, abscesses). ? disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: potassium sorbate; castor oil; titanium dioxide; hypromellose phthalate; maltodextrin; carbomer 934; citric acid; silicon dioxide; xanthan gum; sucrose; povidone; flavour - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis. 6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae; 7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. klacid (clarithromycin) is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; 2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; 3. skin and skin structure infections (eg impetigo); 4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. 5. acute otitis media. note: 1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of klacid in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - clarithromycin - granules for oral suspension - 125

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - clarithromycin - granules for oral suspension - 125mg/5ml

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - clarithromycin - granules for oral suspension - 125 mg/5ml

Kenya - English - Pharmacy and Poisons Board

abbott laboratories s.a. (pty) ltd 219 golf club terrace constantia kloof , - clarithromycin - granules for oral suspension - 125 mg/5ml - other drugs for acid related disorders

Malta - English - Medicines Authority

neofarma pharmaceuticals limited - clarithromycin - granules for oral suspension - clarithromycin 125 milligram(s)/5 millilitre - antibacterials for systemic use

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbott laboratories (m) sdn. bhd. - clarithromycin -